Obi Pharma Inc (4174 TT): Inherent Pipeline Risk Has Clouded Near-Term Outlook
As the lead pipeline candidate did not meet primary endpoint in phase 2 trial and developing breast cancer vaccine is a challenging job, phase 3...
446 Views
Allegations Will Distract Management
Since our last Insight The “Fasten Seat Belt Sign” Remains On posted in December, the Shi Lin District Prosecutors Office filed insider trading...
210 Views
The "Fasten Seat Belt Sign" Remains On
OBI Pharmaceuticals (4174:TT) is a biotechnology company developing treatments for cancer. The shares have declined by 44% since our last Insight...
164 Views
Fasten Your Belts: Air Pockets Ahead
OBI Pharmaceuticals (4174:TT) is a biotechnology company developing treatments for cancer. The company has been mired in controversy for the past...
181 Views